CME group director Charles Carey sells $132,676 in stock

Published 11/06/2025, 14:14
CME group director Charles Carey sells $132,676 in stock

CHICAGO—Charles P. Carey, a director at CME Group Inc. (NASDAQ:CME), recently executed sales of the company’s Class A common stock, according to a filing with the Securities and Exchange Commission. On June 10, Carey sold a total of 500 shares, fetching prices between $265.35 and $265.36 per share. The transactions amounted to a total of $132,676. The sales occurred as CME Group, currently valued at approximately $96 billion, trades near its InvestingPro Fair Value with a "GOOD" financial health rating.

Following these sales, Carey holds 4,900 shares directly through a trust. The sales were conducted in two separate transactions of 150 and 350 shares, respectively. This activity follows routine trading practices by insiders, providing a glimpse into the stock management strategies of company executives. InvestingPro data shows CME has maintained dividend payments for 23 consecutive years, with a current dividend yield of 4.06% and recent dividend growth of 9.64%. Get deeper insights into CME’s insider trading patterns and comprehensive analysis with an InvestingPro subscription.

In other recent news, CME Group reported a record average daily trading volume for May 2025, with 28.9 million contracts traded, marking an 11% increase from the previous year. This robust trading activity spanned various asset classes, including interest rates, metals, and cryptocurrencies. UBS analysts reaffirmed a Buy rating on CME Group stock, although they slightly adjusted their earnings per share estimate for the second quarter of 2025 due to moderated futures volume. Despite this, UBS remains optimistic about the company’s future, citing strong cash market activity and ongoing geopolitical uncertainties. In contrast, Erste Group downgraded CME Group stock from Buy to Hold, citing an expected slowdown in turnover and net profit growth. Barclays (LON:BARC) maintained an Equalweight rating, noting a 4% month-over-month revenue increase from BrokerTec and EBS in April. Additionally, CME Group announced the launch of four new cryptocurrency reference rates in collaboration with CF Benchmarks, expanding their offerings to include Arbitrum, Ondo, NEAR, and Sui. This move aims to provide transparent pricing data for these digital assets as the cryptocurrency market matures.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.